^
    Back
    Association details:
    Biomarker:MRE11A mutation
    Cancer:Mesothelioma
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JTO Clin Res Rep
    Title:

    Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene

    Published date:
    09/17/2021
    Excerpt:
    A total of 23 previously treated patients with pleural and peritoneal mesothelioma were enrolled and treated (germline BAP1, n = 4; germline MRE11A...The median PFS of germline BAP1 mutants (n = 4) was 2.3 months (95% CI: 1.3-3.6 mo) versus 4.1 months (95% CI: 2.7-5.5 mo) for wild-type (n = 19; p = 0.019).
    DOI:
    10.1016/j.jtocrr.2021.100231
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.

    Published date:
    05/13/2020
    Excerpt:
    Phase II single-center study (NCT03531840) enrolled patients with advanced pleural or peritoneal mesothelioma...Median olaparib cycles received was 4 (2-21)....Patient with PR had a germline mutation in MRE11A.
    DOI:
    10.1200/JCO.2020.38.15_suppl.9054
    Trial ID:
    NCT03531840